Mabworks
Beijing
About Mabworks
Beijing Mabworks Biotech, a gene engineering mAb company. Mabworks is working on ZMapp, an Ebola treatment developed by San Diego's MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech's Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Total funding: $214.5M
- Funding stage: IPO
- Last round: Series C (Apr 2020)
- Ticker: neeq:874070
- Website: mab-works.com
- Phone: +86(0)01-87169780
Industries & Categories
Biopharma, Biotechnology, Clinical Trials
Social Profiles
Canonical: https://fsome.com/organization/mabworks-123531 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.